RVPH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. RVPH is in a clear downtrend (bearish moving averages, price sitting on support at ~$0.29) with no Intellectia buy signals and a major FDA setback that increases the probability of dilution to fund another Phase 3 trial. Given an impatient approach (unwilling to wait for a cleaner setup), the risk/reward is unfavorable at current levels; I would avoid new buys and treat it as a sell/stand-aside until price reclaims key resistance levels and financing risk is clearer.
Trend is bearish: SMA_200 > SMA_20 > SMA_5 confirms a sustained downtrend. Price (~0.29) is testing S1 support at 0.29; a clean break likely exposes S2 near 0.271. RSI_6 is ~29.6, which is oversold/near-oversold and can allow for short bounces, but oversold signals are less reliable when the broader trend is bearish. MACD histogram is slightly positive (0.00356) but positively contracting, suggesting bullish momentum is weak and fading rather than expanding. Key upside levels to reverse the immediate damage are pivot 0.322, then resistance at 0.354–0.374; without a reclaim of ~0.322, rallies are more likely to be sold.
Technical: near-term oversold/near-oversold conditions at a defined support (0.
can produce a reflex bounce, especially in microcaps.
Options sentiment is aggressively call-skewed, which can support sharp upside moves on any favorable headline.
Pattern-based projection data suggests potential positive drift over 1 week to 1 month (+3.08% next week; +7.87% next month), though near-term (next day) is slightly negative in the same model.
Regulatory setback: FDA denied the company’s request to file an NDA without a second Phase 3 schizophrenia study—this materially extends timeline and increases execution risk.
Financing/dilution risk: analyst specifically expects equity dilution; company reportedly needs ~$60M–$75M to execute another Phase 3, which is significant relative to its microcap size.
Technical downtrend remains intact (bearish MA stack); if 0.29 fails, next support is ~0.271 with limited structure below.
No supportive news flow in the last week to act as a near-term catalyst.
Latest reported quarter: 2025/Q3. Revenue remains effectively $0 (no commercialized revenue), while losses widened: Net Income fell to -$4.01M (down ~52% YoY) and EPS declined to -0.06 (down ~76% YoY). This is consistent with a pre-revenue biotech profile where cash burn is the key issue; with an additional Phase 3 likely required, the financial trajectory increases the probability of near-term capital raising.
Recent analyst trend: Roth Capital reiterated a Buy but cut its price target sharply to $1.50 from $3 (2025-12-23) after the FDA denial regarding filing an NDA without a second Phase 3 study. Wall Street pro view (pros): continued optimism on brilaroxazine potential and upside optionality if clinical/regulatory path improves. Cons: longer timeline, higher cost to completion, and meaningful dilution risk to fund the required Phase 3; these cons dominate near-term decision-making. Politicians/congress: no recent congress trading data available; hedge fund and insider activity are described as neutral with no significant recent trends.
